Loading...
Loading...
Tarsier Pharma Ltd.
Tarsier Pharma Ltd.. Spoken Alpha tracks TARX's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks TARX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 5/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TARX.
curl https://api.spokenalpha.com/v1/companies/TARX| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.01 | $3.85 | +4.2% | +1.5% | +2.6% |
| Q4 FY2026 | $4.11 | $3.96 | +3.7% | -1.1% | -3.3% |
| Q3 FY2026 | $4.00 | $3.89 | +2.8% | -3.1% | -3.5% |
| Q2 FY2026 | $4.15 | $4.06 | +2.1% | +2.6% | +4.9% |
| Q1 FY2025 | $3.72 | $4.08 | -8.8% | +6.2% | +8.3% |
| Q4 FY2025 | $3.75 | $4.11 | -8.8% | +5.8% | +4.8% |
| Q3 FY2025 | $4.07 | $4.01 | +1.4% | +7.7% | +4.9% |
| Q2 FY2025 | $3.73 | $4.10 | -9.1% | -2.6% | -5.2% |
| Q1 FY2024 | $3.74 | $4.22 | -11.4% | +0.2% | +0.5% |
| Q4 FY2024 | $3.92 | $4.04 | -3.0% | +6.2% | +7.9% |